| (Values in U.S. Thousands) | Dec, 2011 | Jun, 2018 | Mar, 2018 | Dec, 2017 | Sep, 2017 |
| Sales | 0 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | -1,980 | 0 | 0 | 0 | 0 |
| Net Income Growth | unch | unch | unch | unch | unch |
Pharmos Corp (PARS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Pharmos Corporation is a bio-pharmaceutical company that discovers and develops novel therapeutics to treat a range of inflammatory and neurological disorders such as traumatic brain injury and stroke. Theyhave an extensive portfolio of drug candidates under development, as well as discovery, preclinical and clinical capabilities.